PriceTargets.com logo

Quanterix - QTRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.25
  • Forecasted Upside: 103.23%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.44 As of 11/15/2024 01:00 AM ET
▼ -0.48 (-4.03%)

This chart shows the closing price for QTRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quanterix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QTRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QTRX

Analyst Price Target is $23.25
▲ +103.23% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Quanterix in the last 3 months. The average price target is $23.25, with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 103.23% upside from the last price of $11.44.

This chart shows the closing price for QTRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 polled investment analysts is to moderate buy stock in Quanterix. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/13/2024TD CowenBoost TargetHold ➝ Hold$13.50 ➝ $16.00
8/12/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $28.00
8/9/2024TD CowenLower TargetHold ➝ Hold$17.00 ➝ $15.00
7/9/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$35.00 ➝ $24.00
4/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$32.00 ➝ $25.00
3/4/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $32.00
2/1/2024ScotiabankInitiated CoverageSector Outperform$30.00
10/2/2023The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
9/27/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$30.00 ➝ $34.00
9/25/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$25.00 ➝ $32.00
9/25/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$25.00 ➝ $32.00
8/9/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$27.00 ➝ $30.00
8/8/2023Leerink PartnrsUpgradeMarket Perform ➝ Outperform
8/8/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$30.00
5/23/2023The Goldman Sachs GroupUpgradeNeutral ➝ Buy$13.00 ➝ $27.00
11/10/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $13.00
11/9/2022Leerink PartnersBoost TargetMarket Perform$12.00 ➝ $15.00
8/16/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold
8/15/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$40.00 ➝ $12.00
8/10/2022The Goldman Sachs GroupLower TargetNeutral$25.00 ➝ $15.00
8/9/2022CowenDowngradeOutperform ➝ Market Perform
8/9/2022CowenDowngradeOutperform ➝ Market Perform$38.00 ➝ $18.00
8/9/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$35.00 ➝ $15.00
7/14/2022The Goldman Sachs GroupLower TargetNeutral$30.00 ➝ $25.00
5/11/2022CowenLower Target$60.00 ➝ $38.00
5/11/2022CowenLower Target$60.00 ➝ $38.00
4/13/2022The Goldman Sachs GroupLower TargetNeutral$40.00 ➝ $35.00
3/2/2022JPMorgan Chase & Co.Lower TargetOverweight$85.00 ➝ $60.00
3/2/2022Leerink PartnersLower TargetOutperform$70.00 ➝ $50.00
3/2/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral$40.00
6/10/2021Leerink PartnersReiterated RatingBuy
6/4/2021The Goldman Sachs GroupInitiated CoverageSell$53.00
5/6/2021Leerink PartnersLower TargetOutperform$85.00 ➝ $70.00
3/3/2021Leerink PartnersBoost TargetOutperform$75.00 ➝ $85.00
1/27/2021Leerink PartnersBoost TargetOutperform$50.00 ➝ $75.00
11/6/2020Leerink PartnersBoost TargetOutperform$48.00 ➝ $50.00
10/19/2020Leerink PartnersBoost TargetOutperform$37.00 ➝ $48.00
8/5/2020JPMorgan Chase & Co.Boost TargetOverweight$30.00 ➝ $40.00
8/5/2020Leerink PartnersBoost TargetOutperform$35.00 ➝ $37.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 7 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 8 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 8 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Quanterix logo
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $11.44
Low: $11.22
High: $11.98

50 Day Range

MA: $12.95
Low: $11.06
High: $15.49

52 Week Range

Now: $11.44
Low: $10.50
High: $29.70

Volume

555,932 shs

Average Volume

445,914 shs

Market Capitalization

$439.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of Quanterix?

The following Wall Street analysts have issued reports on Quanterix in the last twelve months: Canaccord Genuity Group Inc., Scotiabank, TD Cowen, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for QTRX.

What is the current price target for Quanterix?

0 Wall Street analysts have set twelve-month price targets for Quanterix in the last year. Their average twelve-month price target is $23.25, suggesting a possible upside of 103.2%. Scotiabank has the highest price target set, predicting QTRX will reach $28.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $16.00 for Quanterix in the next year.
View the latest price targets for QTRX.

What is the current consensus analyst rating for Quanterix?

Quanterix currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for QTRX.

What other companies compete with Quanterix?

Other companies that are similar to Quanterix include Pacific Biosciences of California, Fluidigm, Transcat, Cytek Biosciences and Standard BioTools. Learn More about companies similar to Quanterix.

How do I contact Quanterix's investor relations team?

Quanterix's physical mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company's listed phone number is (617) 301-9400 and its investor relations email address is [email protected]. The official website for Quanterix is www.quanterix.com. Learn More about contacing Quanterix investor relations.